Generic APIs
Generic peptide, oligo, and small molecule offerings
GENERICS

Generic API Services

Sinopep is a trusted global supplier of high-quality peptide APIs intended solely for laboratory R&D, further manufacturing, or compounding by licensed pharmacies under applicable regulations (e.g., 21 U.S.C. § 353a/b and relevant state laws).
Our extensive portfolio includes dozens of generic peptide APIs supported by active Type II DMFs and four successful U.S. FDA inspections. These APIs are supplied as bulk drug substances only, are not finished pharmaceutical products, are not approved by the FDA for any therapeutic use, and carry no trademark rights or licenses from originator companies.
All marketing references are for identification purposes only and do not imply equivalence, endorsement, or authorization by brand owners. Partners are solely responsible for ensuring their use complies with current patent, trademark, and compounding regulations.

Peptides APIs
Sinopep holds DMFs for dozens of widely used generic peptide APIs, supporting partners with reliable quality and global regulatory compliance.
Oligo APIs
Our oligo platform has achieved significant milestones in oligonucleotide development, including the successful synthesis of various types of oligos such as ASO, SiRNA, and PMO.
Small Molecule APIs
At Sinopep, our scientists have spent over two decades mastering the large-scale, stereoselective synthesis of complex intermediates and APIs with multiple chiral centers.
Generics

Generic Peptide API Services

Sinopep is a trusted global supplier of high-quality peptide APIs intended solely for laboratory R&D, further manufacturing, or compounding by licensed pharmacies under applicable regulations (e.g., 21 U.S.C. § 353a/b and relevant state laws). With over two decades of expertise in peptide synthesis and manufacturing, Sinopep employs advanced hybrid solid-phase and liquid-phase technologies to produce complex peptides at scales ranging from grams to multi-kilogram batches, ensuring exceptional purity, consistency, and scalability. Our extensive portfolio encompasses a wide range of generic peptide APIs, supported by active Type II DMFs and a proven track record of four successful U.S. FDA inspections demonstrating unwavering commitment to regulatory excellence and quality standards. These APIs are bulk drug substances only, are not finished pharmaceutical products, are not approved by the FDA for any therapeutic use, and are provided without any implied licenses or authorizations. All marketing references are for identification purposes only and do not suggest equivalence, endorsement, or approval for clinical applications. Partners are solely responsible for ensuring their use complies with current regulatory, compounding, and intellectual property requirements.

Generic Peptide API Pipeline

R&D Pilot Validation DMF Filed NDA Commercial
Eptifibatide (US / EU / CN)
Bivalirudin (US / EU / UK / CA / AU / SA / IL / CN)
Cetrorelix Acetate (US / SA / IL / JO / CN)
Lanreotide Acetate (US / EU / UK)
Octreotide Acetate (US / EU / CA / SA / RU / CN)
Thymalfasin
Liraglutide* (US / EU / UK / CA / ANVISA / CN)
Semaglutide* (US / KR / EU / ANVISA / CN)
Tirzepatide* (US)
Atosiban Acetate (CN)
Desmopressin Acetate
Edotreotide
Oxytocin
Teriparatide
Plecanatide
Teduglutide
Ziconotide
Amycretin
Petrelintide
Icotrokinra (JNJ-2113)
Enlicitide Chloride (MK-0616)
Cagrilintide
Pegcetacoplan
Eloralintide
Retatrutide

* Disclaimer: Due to the limitation of patent protection, commercial production and sales will not be carried out for the time being, and will only be used for scientific research and administrative approval.

Generics

Oligonucleotide API Services

Sinopep’s oligonucleotide technology platforms are equipped with state-of-the-art systems, including Cytiva OligoSynt/OligoPilot solid-phase synthesizers and AKTA Avant/Process purification equipment, enabling API production from milligram to kilogram scale. These platforms support comprehensive CRDMO services, covering the development and manufacturing of both drug substance and drug product from pre-clinical through clinical stages.

Generic Peptide API Pipeline

R&D Pilot Validation DMF Filed NDA Commercial
Inclisiran (US DMF)*
Nusinersen* (DMF in Preparation)
Givosiran*
Patisiran*
Vutrisiran*
Tofersen
Eteplirsen
Golodirsen
Imetelstat
Avacincaptad Pegol

* Disclaimer: Due to the limitation of patent protection, commercial production and sales will not be carried out for the time being, and will only be used for scientific research and administrative approval.

Generics

Small Molecule API Services

Over half of all marketed drugs are chiral, with most utilizing a single, therapeutically active enantiomer. At Sinopep, our scientists have spent over two decades mastering the large-scale, stereoselective synthesis of complex intermediates and APIs with multiple chiral centers. Our Asymmetric Synthesis Platform offers a comprehensive, one-stop solution for integrating chirality through biocatalysis, asymmetric hydrogenation and reductions, enantioselective coupling reactions, and chiral auxiliary-assisted methodologies.

Generic Peptide API Pipeline

R&D Pilot Validation DMF Filed NDA Commercial
Fulvestrant (US DMF / CN CDE / CEP / ANVISA / RUS / KDMF / CAN / JPN)
Oseltamivir Phosphate (US DMF / EDMF / CN CDE)
Alogliptin Benzoate* (CEP Plan / CN CDE)
Epalrestat (CN CDE)
Sodium Picosulfate (CN CDE)
Atorvastatin Calcium (CN CDE)
Bumetanide (CN CDE)
Sulindac (CN CDE)
Risdiplam* (US DMF)
Elacestrant* (US DMF)
Orforglipron* (US DMF)
Ubrogepant* (US DMF)
Bifonazole (DMF in Preparation)
Slidenafil Citrate (DMF in Preparation)
Decoquinate (DMF in Preparation)
Ezetimibe (DMF in Preparation)
Roxadustat* (DMF in Preparation)
Dydrogesterone (DMF in Preparation)

* Disclaimer: Due to the limitation of patent protection, commercial production and sales will not be carried out for the time being, and will only be used for scientific research and administrative approval.